

# SECURITIES AND EXCHANGE COMMISSION

## FORM 3

Filing Date: **2013-01-28** | Period of Report: **2013-01-16**  
SEC Accession No. [0000914475-13-000013](#)

([HTML Version](#) on [secdatabase.com](#))

### REPORTING OWNER

#### **Gano Kyle**

CIK: **1567160**

Type: **3** | Act: **34** | File No.: **000-22705** | Film No.: **13552921**

Mailing Address

*NEUROCRINE*

*BIOSCIENCES, INC.*

*12780 EL CAMINO REAL*

*SAN DIEGO CA 92130*

### ISSUER

#### **NEUROCRINE BIOSCIENCES INC**

CIK: **914475** | IRS No.: **330525145** | State of Incorpor.: **CA** | Fiscal Year End: **1231**

SIC: **2836** Biological products, (no diagnostic substances)

Mailing Address

*12780 EL CAMINO REAL*

*SAN DIEGO CA 92130*

Business Address

*12780 EL CAMINO REAL*

*SAN DIEGO CA 92130*

*(858) 617-7600*

# FORM 3

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0104
Expires:	02/28/2011
Estimated average burden hours per response	0.5

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section  
17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the  
Investment Company Act of 1940

<b>1. Name and Address of Reporting Person</b> <u>Gano Kyle</u> (Last) (First) (Middle) NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL (Street) SAN DIEGO, CA 92130 (City) (State) (Zip)	<b>2. Date of Event Requiring Statement (Month/Day/Year)</b> 01/16/2013	<b>3. Issuer Name and Ticker or Trading Symbol</b> <u>NEUROCRINE BIOSCIENCES INC [NBIX]</u> <b>4. Relationship of Reporting Person(s) to Issuer</b> (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) <u>Chief Business Dev Officer</u> <b>5. If Amendment, Date Original Filed (Month/Day/Year)</b>  <b>6. Individual or Joint/Group Filing</b> (Check applicable line) <input checked="" type="checkbox"/> Form Filed by One Reporting Person <input type="checkbox"/> Form Filed by More than One Reporting Person
---	--	---

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	22,488	D	

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Employee Stock Option (right to buy)	(1)	09/26/2013	Common Stock	2,400	\$10.9	D	
Employee Stock Option (right to buy)	(2)	03/12/2015	Common Stock	9,000	\$5	D	
Employee Stock Option (right to buy)	(3)	05/11/2017	Common stock	40,000	\$2.59	D	
Employee Stock Option (right to buy)	(4)	08/25/2021	Common Stock	75,000	\$5.76	D	
Employee Stock Option (right to buy)	(5)	01/12/2022	Common Stock	70,000	\$8.66	D	
Employee Stock Option (right to buy)	(6)	01/10/2023	Common Stock	60,000	\$8.65	D	
Restricted Stock Unit	(7)	(7)	Common Stock	10,000	\$ 0 (8)	D	

**Explanation of Responses:**

1. The option vested in annual installments over three years. The first installment became exercisable on September 26, 2007.
2. The option vested in annual installments over three years. The first installment became exercisable on March 12, 2009.
3. The option vests in monthly installments over three years. The first installment became exercisable on June 11, 2010.
4. The option vests in monthly installments over three years. The first installment became exercisable on September 25, 2011.
5. The option vests in monthly installments over four years. The first installment became exercisable on February 12, 2012.
6. The option vests in monthly installments over four years. The first installment becomes exercisable on February 10, 2013.
7. The restricted stock units will vest annually at 1/4 of the units vesting on January 10, 2014, January 10, 2015, January 10, 2016 and January 10, 2017, respectively.
8. Each restricted stock unit represents a contingent right to receive one share of Neurocrine Biosciences, Inc. Common Stock.

**Signatures**

Margaret E. Valeur- Jensen, By Power of Attorney

\*\* Signature of Reporting Person

01/28/2013

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**

